140 related articles for article (PubMed ID: 38062319)
1. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2.
Gong Z; Xue L; Vlantis AC; van Hasselt CA; Chan JYK; Fang J; Wang R; Yang Y; Li D; Zeng X; Tong MCF; Chen GG
J Endocrinol Invest; 2024 May; 47(5):1271-1280. PubMed ID: 38062319
[TBL] [Abstract][Full Text] [Related]
2. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
3. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
4. Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway.
Yu X; He Z; Wang Z; Ke S; Wang H; Wang Q; Li S
Exp Cell Res; 2024 May; 438(2):114053. PubMed ID: 38663476
[TBL] [Abstract][Full Text] [Related]
5. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
6. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
7. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
[TBL] [Abstract][Full Text] [Related]
9. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
10. Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras
Kumar G; Madka V; Singh A; Farooqui M; Stratton N; Lightfoot S; Mohammed A; Rao CV
Neoplasia; 2021 Jun; 23(6):574-583. PubMed ID: 34091121
[TBL] [Abstract][Full Text] [Related]
11. KRAS G12D mutation eliminates reactive oxygen species through the Nrf2/CSE/H
Fan K; Zhang S; Ni X; Shen S; Wang J; Sun W; Suo T; Liu H; Ni X; Liu H
Acta Biochim Biophys Sin (Shanghai); 2022 Nov; 54(11):1731-1739. PubMed ID: 36514219
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic KRAS confers chemoresistance by upregulating NRF2.
Tao S; Wang S; Moghaddam SJ; Ooi A; Chapman E; Wong PK; Zhang DD
Cancer Res; 2014 Dec; 74(24):7430-41. PubMed ID: 25339352
[TBL] [Abstract][Full Text] [Related]
13. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
14. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer.
Tao S; Rojo de la Vega M; Chapman E; Ooi A; Zhang DD
Mol Carcinog; 2018 Feb; 57(2):182-192. PubMed ID: 28976703
[TBL] [Abstract][Full Text] [Related]
15. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer.
Morrison JA; Pike LA; Sams SB; Sharma V; Zhou Q; Severson JJ; Tan AC; Wood WM; Haugen BR
Mol Cancer; 2014 Mar; 13():62. PubMed ID: 24645981
[TBL] [Abstract][Full Text] [Related]
16. The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.
Yang H; Xiang S; Kazi A; Sebti SM
J Biol Chem; 2020 Mar; 295(10):3055-3063. PubMed ID: 32001619
[TBL] [Abstract][Full Text] [Related]
17. The ROS-KRAS-Nrf2 axis in the control of the redox homeostasis and the intersection with survival-apoptosis pathways: Implications for photodynamic therapy.
Ferino A; Rapozzi V; Xodo LE
J Photochem Photobiol B; 2020 Jan; 202():111672. PubMed ID: 31778952
[TBL] [Abstract][Full Text] [Related]
18. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.
Pan LN; Ma YF; Li Z; Hu JA; Xu ZH
Cell Biol Int; 2021 Apr; 45(4):795-803. PubMed ID: 33325140
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.
Yang L; Shen C; Estrada-Bernal A; Robb R; Chatterjee M; Sebastian N; Webb A; Mo X; Chen W; Krishnan S; Williams TM
Nucleic Acids Res; 2021 Nov; 49(19):11067-11082. PubMed ID: 34606602
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
